• What CMC Means for mRNA-LNP Translation

  2026-10-12

  Liu and colleagues review how lipid chemistry, manufacturing variables, analytical characterization, and comparability planning shape the translation of mRNA lipid nanoparticles. The article is a conceptual CMC framework rather than a primary experimental study, so its conclusions are useful for organizing evidence but do not establish universal formulation or manufacturing rules.

• What the CAF04 mRNA Liposome Study Shows

  2026-10-12

  A 2026 murine study found that a two-component cationic liposome platform could deliver antigen-encoding mRNA and produce antitumor CD8+ T-cell responses. The findings support a formulation-platform hypothesis, but they do not establish that a particular DOTMA product, supplier, or formulation is clinically effective or interchangeable with the study materials.

• QPRT, P2Y11 Signaling, and Breast Cancer Invasion

  2026-10-10

  A 2021 study links elevated quinolinate phosphoribosyltransferase (QPRT) with breast cancer invasiveness and proposes a connection between NAD+ metabolism, P2Y11 signaling, and myosin light-chain phosphorylation. Its findings support a mechanistic research model, but remain preclinical and do not establish clinical efficacy or therapeutic applicability.

• Itraconazole and Candida Biofilm Resistance

  2026-10-09

  Itraconazole is more than a triazole antifungal agent in translational research: it is a useful probe for separating fungal drug response from host pharmacology. This article interprets new evidence linking PP2A, autophagy, and Candida albicans biofilm resistance, while clarifying what the study establishes, what remains untested for Itraconazole, and how researchers can build a more rigorous translational evidence package.

• From Organoids to Mechanism: Crizotinib in Context

  2026-10-09

  A source-grounded perspective on how Crizotinib hydrochloride can be evaluated as a mechanistic probe in patient-derived gastric cancer assembloids, with emphasis on tumor–stroma effects, evidence boundaries, and translational interpretation.

• Nelfinavir Mesylate Beyond Viral Protease

  2026-10-08

  Nelfinavir Mesylate sits at the intersection of established HIV-1 protease inhibition and emerging ferroptosis biology. This thought-leadership analysis examines how the DDI2–NFE2L1–ubiquitin-proteasome axis may connect proteostasis to oxidative cell death, while separating reported findings from translational interpretation. It also considers assay strategy, evidence boundaries, product provenance, and the opportunities and risks of repurposing a clinically known compound as a mechanistic research probe.

• Ertapenem Sodium Salt and Resistance Evidence

  2026-10-08

  Ertapenem sodium salt can serve as a mechanistic anchor for interpreting carbapenem-resistance phenotypes. This article connects its pharmacology with the 2025 Guangdong CREC study while emphasizing evidence strength, transmission boundaries, and research-use limitations.

• Auranofin: Evidence, Applications, and Limits

  2026-10-07

  A source-grounded overview of Auranofin as a reported thioredoxin reductase inhibitor, emphasizing redox biology, cancer research, radiosensitization, apoptosis, evidence quality, and the limits of connecting supplier claims with recent metabolic oncology findings.

• hCG, H3K27me3, and CXCL10 in Human Decidua

  2026-10-07

  Silasi et al. show that human chorionic gonadotropin links placental signaling to epigenetic repression of CXCL10 in decidual stromal cells through EZH2-dependent H3K27me3 enrichment. The study provides a mechanistic framework connecting hormone signaling, chromatin state, chemokine expression, and CD8-cell recruitment at the maternal–fetal interface.

• Low-Molecular Weight Inhibitors of the Alternative Pathway

  2026-10-06

  This invited review explains why complement factor B and factor D became leading targets for selective, low-molecular-weight control of the alternative complement pathway. It connects pathway mechanism, drug-discovery constraints, and early translational evidence while emphasizing the boundaries between biochemical activity, disease models, and clinical development.

• DMXAA (Vadimezan): Evidence, Mechanism and Limits

  2026-10-06

  A source-grounded overview of DMXAA (Vadimezan), focusing on its proposed role in vascular disruption and STING-activating nanomedicine, the strength of current preclinical evidence, and the boundaries of interpretation.

• Bradykinin B2 Receptors and Ileal Peristalsis

  2026-10-05

  Chan and Rudd showed that bradykinin inhibits the peristaltic reflex in isolated guinea pig ileum through B2, rather than B1, kinin receptors. Their antagonist-based pharmacology linked receptor identity to a functional motility endpoint while also revealing important distinctions between receptor blockade and direct effects on peristalsis.

• Propranolol: Evidence, Context, and Limitations

  2026-10-05

  A source-grounded overview of propranolol as a non-selective β-adrenergic receptor blocker, emphasizing historical hypertension findings, conceptual research applications, evidence quality, and limits on translation to cardiovascular, memory, tremor, and metabolic research.

• AmpliFold Capture-and-Release in Lateral Flow Assays

  2026-10-04

  The 2025 ACS Sensors study introduces AmpliFold, a capture-and-release architecture designed to reduce the kinetic constraints that limit lateral flow assay sensitivity. In a HER2 model, the strategy produced reported sensitivity improvements of up to 16-fold, although the evidence remains a proof of concept based mainly on engineered assay formats and spiked samples.

• From Cell State to CMC: A Translational Lens

  2026-10-03

  mRNA–lipid nanoparticle translation is often framed as a formulation and manufacturing challenge, but the biological state of cells used in potency and uptake assays can also shape interpretation. This thought-leadership article connects the CMC framework described by Liu et al. with a fit-for-purpose strategy for evaluating serum-free cell cryopreservation as a pre-analytical variable—without treating a cell-freezing medium as a substitute for LNP quality controls.

8562 records 1/571 page Next 12345 下5页 Last page